ReviR Therapeutics Achieves IND Approval for RTX-117 in Both China and the U.S., Triggering Milestone Payment to Xintec

Gelonghui January 14 | XtalPi announced on January 14 that its incubated company ReviR Therapeutics’ innovative drug pipeline RTX-117 has recently achieved the milestone of "dual filing and dual approval" (IND approval) in both China and the United States. Combined with the successful progress of multiple collaborations, XtalPi will receive milestone payments totaling several tens of millions of Hong Kong dollars from ReviR. ReviR will continue to complete the subsequent clinical development of RTX-117, and XtalPi has the right to participate in the sales revenue sharing and subsequent licensing revenue sharing of this pipeline.